Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units

Initial Phase of Severe Sepsis and Septic Shock Clinical Trial

Official title:

Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02213796
• Other study ID #: MEROICU14
• Status: Completed
• Phase: Phase 4
• First received: August 8, 2014
• Last updated: August 8, 2014
• Start date: January 2013
• Est. completion date: December 2013

Study information

• Verified date: August 2014
• Source: Prince of Songkla University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Thailand: Ethical Committee, Faculty of Medicine, Prince of Songkla University
• Study type: Interventional

Clinical Trial Summary

This is a prospective, noncomparative study to assess the pharmacodynamics of meropenem during early phase of severe sepsis and septic shock in critically ill patients in an intensive care unit.

Clinical and laboratory data such as age,sex, body weight, electrolyte, vital signs, APACHE II score, SOFA score, BUN, Cr and blood culture will be collected.

Twelve patients will be enrolled in this study. Meropenem pharmacokinetic will be carried out during the first and second dose after 1g meropenem administration. Blood samples (approximately 3 ml) will be obtained by direct venepuncture at the following time: 0, 0.25, 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 8, 8.5, 9, 9.5, 10, 12, 14 and 16 h.

Meropenem assays will be performed by modified method of Ozkan et al. (Biomed. Chromatogr., 2001).

The pharmacokinetics of meropenem will be modelled from concentration-time profile using compartmental model. Monte Carlo simulation to assess PK/PD index as 40% and 100% T>MIC will be conducted and the results will be reported as % PTA (Probability Target Attainment) and %CFR (Cumulative Faction Response)

Description:

Introduction:

Severe sepsis/septic shock are one of the most important reasons for admission the critically-ill patient to Intensive Care Units (ICU) and remaining a major causes of high mortality. Evidently, the fluctuation in pathophysiology, particularly during early phase, of this condition may result in PK alteration and lead to the inadequate antibiotic dosed of standard treatment. Therefore, thearly phase treatment with an appropriate antimicrobial doses that achieved pharmacodynamic target for antimicrobial therapy have been the crucial factor for therapeutic.

Meropenem, a carbapenem antibiotic, is a β-lactam antimicrobial agent with a broad spectrum of activity, coverage of gram-negative bacteria including highly resistant pathogens for instance ESBL-producing or AmpC-mediated b-lactamase producing Enterobacteriaceae. This agent, in common with other β-lactams, is characterized by time-dependent antimicrobial activity, and the exposure time during which the free drug concentrations remains above the minimum inhibitory concentration (T>MIC) is the pharmacokinetic/pharmacodynamic (PK/PD) index that best correlates with efficacy. The majority of previous PK/PDs studies on β-lactams in critically ill patients were mostly conducted in the steady-state period of treatment in which during the early phase of severe sepsis/septic shock was still lacking.

Objectives:

To study the population PK of meropenem and assess the probability of target attainment (PTA) of meropenem inthe initial phases of severe sepsis or septic shock patients in order to be able to optimize dosing recommendations.

Clinical and laboratory data:

Age, sex, body weight, electrolite, vitalsigns, APACHAE II score, BUN, Cr, blood culture

Drug preparation and administration:

The dosage of meropenem was 1-h infusion of 1g diluted in 100 mL of normal saline solution via infusion pump at a constant flow rate every 8 h (q8h) for 16 hours.

Study design:

Prospective non-comparative studyof 9 patients during the initial 24 h of severe sepsis or septic shock. Each subject received a 1-h infusion of 1 g q8h of meropenem for 16 hrs. Monte Carlo simulation were attempted to analyze the pharmacokinetics of experimental data.

Sample collection:

Meropenem PK studies were carried out during the administration of the first and second dose of meropenem (0-16 h after the start of administration of meropenem). Blood samples (ca. 3 mL) were obtained by direct venipuncture at the following times: shortly before (time 0) and then at 0.25, 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 8, 8.5, 9, 9.5, 10, 12, 14 and 16 h after the start of administration of meropenem. All blood samples were added to a heparinized tube, were immediately stored on ice and were centrifuged at 2000 × g at 4◦C for 10 min within 5 min. All plasma samples were stored at -80◦C until analysis within 1 week.

Moropenem assay:

The meropenem assays by method of Ozkan et al. (Biomed Chromatogr, 2001) will be performed at Department of Medicine, Faculty of Medicine.

Duration of study:

Patients will receive a 1-h infusion of 1 g q8h of meropenem for 16 hrs.

Pharmacokinetic and pharmacodynamic analysis:

Concentration of meropenem in plasma will be simulated in Monte Carlo technique to get PK/PD index (40% and 80% PTA)

Sample size: Nine patients with severe sepsis and septic shock.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient age > 18 years

2. Patients who diagnosed as severe sepsis or septic shock, either at admission or during the ICU stay. Sepsis is the systemic response to infections defined by two or more of the following conditions: body temperature of >38 oC or <36 oC; heart rate of > 90 beats per min; respiratory rate of >20 breaths per min or a PaCO2 of <32 mmHg; or leucocyte count >12,000 cell/mm3, <4,000 cell/mm3 or 10% immature (band) forms. Severe sepsis is defined by sepsis associated with organ dysfunction, hypoperfusion, or hypotension (systolic arterial pressure <90 mmHg, mean arterial pressure <70 mmHg or a reduction of =40 mmHg from baseline). Septic shock is defined by severe sepsis associated with hypotension despite adequate fluid resuscitation

Exclusion Criteria:

1. Patients who are pregnant.

2. Patients who have documented hypersensitivity to carbapenems.

Study Design

Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Critical Illness
• Initial Phase of Severe Sepsis and Septic Shock
• Sepsis
• Shock
• Shock, Septic
• Toxemia

Intervention

Drug:
• Meropenem

Locations

Country	Name	City	State
Thailand	Prince of Songkla University	Hat Yai	Songkhla

Sponsors (2)

Lead Sponsor	Collaborator
Sutep Jaruratanasirikul	Prince of Songkla University

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentration of meropenem in plasma	Concentration of meropenem inplasma will be simulated in Monte Carli simulation to assess PK/PD index as 40% and 100 T>MIC and will be reported as %PTA.	16 hour after first dose	No